Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
- Not stated
- Not stated
- Nov 3, 2026
Official announcement on Grants.gov · opens the funder's page. Always confirm dates there.
Summary
The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers…
Preparing an application?
On Plus, $39 a month
- The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
More from National Institutes of Health
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
$3M
Cellular Senescence Network (SenNet): SenNet Data Coordination and Integration Center (SenNet DCIC) (UM1 Clinical Trials Not Allowed)
Related by subject
Single Source: Continued Development of the Gabriella Miller Kids First Pediatric Data Resource Center (U2C Clinical Trial Not Allowed)
$3.2M
Genomic Data Generation Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)
$3.5M